Drug-induced liver injury (DILI) is a significant concern in clinical practice, arising from medications, herbs, and dietary ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Research published in JAMA Internal Medicine reveals statins may reduce liver cancer risk by 33% and liver complications by ...

For example, damage from the hepatitis B or C virus, or long term alcohol drinking above the recommended levels or non alcoholic fatty liver disease. Hepatocellular carcinoma is more likely to develop ...

"Liver disease, particularly MASLD and hepatocellular carcinoma ... causing inflammation and potential liver damage. The new drug candidate developed in this study targets two proteins, BCL ...

Alcohol doesn’t just impact the liver, it wreaks havoc on the entire digestive system. From inflamed gums and acid reflux to ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that progresses without symptoms and is associated with significant global public health concerns.

Ursodeoxycholic acid (UDCA), a widely used treatment for cholestatic liver diseases ... which is a key driver of hepatocellular damage in DILI. Read the full story here.

The disease can also raise the risk of liver cancer hepatocellular carcinoma (HCC ... We were told in medical school that once the damage was done, there was no way back. But it is reversible ...